Profound Medical Corp. — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 51/100
What the filing says
Profound Medical reported Q2 2026 revenue of $2.5M (up 12% YoY), with net loss of $9.5M ($0.26/share), a 39% improvement from Q2 2025's $15.7M loss. Approximately $3.1M in TULSA revenue was deferred to Q3 due to shipping logistics; excluding this timing, Q2 revenue would have been $5.6M (153% YoY growth). Operating expenses declined 16% YoY to $13.0M. The company received record new purchase orders exceeding $7.0M in Q2, expanded payer coverage by 18.3M lives, grew TULSA-PRO installed base to 84 units, and reiterated full-year 2026 revenue guidance of $25.0M. Cash position was $38.3M at June 30, 2026; 36.5M shares outstanding.
Why this rating
Material revenue growth trajectory (153% ex-timing) and improving unit economics meaningful for $152M market-cap company; cash runway adequate; payer traction significant but early-stage execution risk remains.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.